FDA-cleared profile

ViewFinder Software Version 1.1

Elaitra Ltd · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Provides a softcopy review environment for screening and diagnostic digital breast tomosynthesis, including visualization and image-enhancement aids.

Clinical role
DBT viewing software that displays two views of the same breast and, when the user points the cursor at tissue in one view, indicates the matching tissue in the other; the interpreting physician makes the diagnosis.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Supports only DBT input from the specified Hologic and GE systems; MR and ultrasound are not within the reviewed input scope.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provides a softcopy review environment for screening and diagnostic digital breast tomosynthesis, including visualization and image-enhancement aids.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Two CC/MLO DBT views of the same breast from specified compatible systems.
  • Who uses it?Intended users: Qualified interpreting physicians.
  • What does the software produce?Output: Matched and correlated tissue indication between views with cursor-guided registration.
  • What is its most important limitation?Key limitation: Supports only DBT input from the specified Hologic and GE systems; MR and ultrasound are not within the reviewed input scope.

Clinical takeaway. Clinical role: Provides a softcopy review environment for screening and diagnostic digital breast tomosynthesis, including visualization and image-enhancement aids.

Evidence takeaway. Evidence from the reviewed source record: No clinical test was conducted for the subject device; FDA reported test data from 28 patients, 34 CC-MLO pairs, and 68 directional matches, with aggregate matching frequency 58/68 (85.3%).

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provides a softcopy review environment for screening and diagnostic digital breast tomosynthesis, including visualization and image-enhancement aids.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
DBT viewing software that displays two views of the same breast and, when the user points the cursor at tissue in one view, indicates the matching tissue in the other; the interpreting physician makes the diagnosis.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "ViewFinder is software which displays two Digital Breast Tomosynthesis (DBT) views of the same breast and dynamically indicates correlated (matched) tissue." … "Users operate the device by pointing the cursor at tissue in one view and ViewFinder indicates the matching tissue in the other view.". Read from the exact FDA decision document on 2026-11-14.

Required input
Two CC/MLO DBT views of the same breast from specified compatible systems.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA input and compatibility scope.

Output and clinician action
Matched and correlated tissue indication between views with cursor-guided registration.
  • Exact FDA submission
  • Checked 2026-09-15

FDA output description.

Care setting
Screening and diagnostic digital breast tomosynthesis reading by qualified interpreting physicians; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "ViewFinder is a dedicated softcopy review environment for both screening and diagnostic digital breast tomosynthesis." … "optimized to support qualified interpreting physicians in both screening and diagnostic reading.". Read from the exact FDA decision document on 2026-11-14.

Intended users
Qualified interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-15

Narrower credential was not established by the packet.

Limitations
Supports only DBT input from the specified Hologic and GE systems; MR and ultrasound are not within the reviewed input scope.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
No clinical test was conducted for the subject device; FDA reported test data from 28 patients, 34 CC-MLO pairs, and 68 directional matches, with aggregate matching frequency 58/68 (85.3%).
  • Exact FDA submission
  • Checked 2026-09-15

This is not sensitivity or specificity.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
No clinical test was conducted for the subject device; FDA reported test data from 28 patients, 34 CC-MLO pairs, and 68 directional matches, with aggregate matching frequency 58/68 (85.3%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

This is not sensitivity or specificity.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

ViewFinder Software Version 1.1 regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K223501
  • Samplen=28
  • IndependenceIndependence not established

K223501

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223501. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Two CC/MLO DBT views of the same breast from specified compatible systems.

    Scope: Exact FDA submission. Exact FDA input and compatibility scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K223501: ViewFinder Software Version 1.1

  2. Routing

    Source context, not route validation: The exact FDA package describes DICOM 3.0 support for ViewFinder, with DICOM-compatible modalities of MG Tomo (mammography tomosynthesis images) and DICOM DSR (Deformable Spatial Registration), an additional conformant modality storing tissue correlation. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "DICOM 3.0 Yes Yes Equivalent None DICOM MG (Digital The subject None compatible Mammography X-Ray) has an" … "modalities MG Tomo MG Tomo additional (Mammography (Mammography conformant Tomosynthesis images) Tomosynthesis images) modality DICOM DSR MR (Magnetic storing tissue (Deformable Spatial Resonance) correlation. Registration) US (Ultrasound)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K223501: ViewFinder Software Version 1.1

  3. AI processing

    Source context, not route validation: The exact FDA package describes ViewFinder as software that runs on a PC in a compatible client/server environment with monitors cleared for mammography, as a standalone application or integrated into medical image management and processing systems. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "ViewFinder runs on a PC and can be used for digital breast tomosynthesis image review together with monitors cleared for mammography diagnostics." … "ViewFinder Software is a software-only solution to run on compatible client server environment together with monitor displays cleared for Mammography.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K223501: ViewFinder Software Version 1.1

  4. Returned objects

    Source context, not route validation: Matched and correlated tissue indication between views with cursor-guided registration.

    Scope: Exact FDA submission. FDA output description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K223501: ViewFinder Software Version 1.1

  5. Viewer/worklist/report

    Unresolved route: Matched and correlated tissue indication between views with cursor-guided registration.

    Scope: Exact FDA submission. FDA output description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K223501: ViewFinder Software Version 1.1

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes ViewFinder as software that runs on a PC in a compatible client/server environment with monitors cleared for mammography, as a standalone application or integrated into medical image management and processing systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "ViewFinder runs on a PC and can be used for digital breast tomosynthesis image review together with monitors cleared for mammography diagnostics." … "ViewFinder Software is a software-only solution to run on compatible client server environment together with monitor displays cleared for Mammography.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes DICOM 3.0 support for ViewFinder, with DICOM-compatible modalities of MG Tomo (mammography tomosynthesis images) and DICOM DSR (Deformable Spatial Registration), an additional conformant modality storing tissue correlation. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DICOM 3.0 Yes Yes Equivalent None DICOM MG (Digital The subject None compatible Mammography X-Ray) has an" … "modalities MG Tomo MG Tomo additional (Mammography (Mammography conformant Tomosynthesis images) Tomosynthesis images) modality DICOM DSR MR (Magnetic storing tissue (Deformable Spatial Resonance) correlation. Registration) US (Ultrasound)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for ViewFinder Software Version 1.1; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223501
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA DBT scope normalized to the controlled mammography/DBT bucket.

Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA breast tomosynthesis scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-04-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K223501 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K223501: ViewFinder Software Version 1.1

    U.S. Food and Drug Administration - Published 2023-04-21 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ViewFinder Software Version 1.1 model card (K223501)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K223501

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K223501 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history